Načítá se...
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)
We conducted a study of combined treatment with docetaxel, bevacizumab, and everolimus in patients with chemotherapy-naive metastatic castrate-resistant prostate cancer. Although we establish a safe dose for coadministration of these 3 agents and our early results suggested encouraging levels of ant...
Uloženo v:
| Vydáno v: | Clin Genitourin Cancer |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7444943/ https://ncbi.nlm.nih.gov/pubmed/28826933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.003 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|